Carlsbad

CARLSBAD, California, September 22, 2011 - Life to Commercialize Influenza Assay for Use on the 7500 Series of Instruments Life Technologies Corporation (NASDAQ:LIFE) today announced that the company has signed an agreement with Quidel Corporation to distribute and commercialize molecular diagnostic assays for the European market.

CARLSBAD, California, September 7, 2011 - SkinMedica, the fastest growing professional skin care company in the United States, has revolutionized the anti-aging category with the introduction of Biometa Essential Serum™ - the first product from SkinMedica to be launched exclusively in select international markets.

CARLSBAD, California, June 2, 2011 - - Further analysis on Ion PGM(TM) will confirm data with goal to develop accurate testing kits to screen samples Life Technologies Corporation today announced that preliminary data from DNA sequencing performed in cooperation with the University Hospital Muenster, Germany, on the Ion Personal Genome Machine (PGM(TM)) strongly suggests that the bacterium at the root of the deadly outbreak in Germany is a new hybrid type of pathogenic E.

CARLSBAD, California, May 28, 2011 - - The Ion Total RNA-Seq Kit, created in partnership with Life Technologies' Ambion(R) division, provides far more accurate and comprehensive data Life Technologies Corporation (www.lifetechnologies.com) (NASDAQ: LIFE) today announced it is now shipping the Ion Total RNA-Seq Kit (find.lifetechnologies.com/ionrnaseq/pr/ion-rnaseq-regional-86MH-784EI.html) for the Ion Personal Genome Machine (PGM(TM)) sequencer, a solution that provides a fast, affordable, easy-to-use alternative to microarrays for transcript expression analysis.

CARLSBAD, California and BERLIN, May 17, 2011 - Life Technologies Corporation (www.lifetech.com/) (NASDAQ: LIFE) and ProBioGen AG (www.probiogen.de/) today announced the availability of Gibco(R) Freedom(TM) Cell Line Development Kits (www.invitrogen.com/freedom.html), a new line of royalty-free products that integrate cells, reagents, culture media and protocols to bring simplicity and flexibility, eliminating up to two months in the earliest stages of new biological drug development.